Philip Beer

Philip Beer has had a long and varied career in the field of medicine and research. In 2021, they were appointed Chief Scientific Officer at Step Pharma and Vice President, Head of Research and Translational Medicine. In this role, they are developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1). In 2020, they were appointed Honorary Professor, Translational Medicine at Hull York Medical School (HYMS) and Chair, Genomics Working Group at British In Vitro Diagnostics Association (BIVDA). In 2017, they were appointed Clinical Cancer Genomics at NHS and ICGC ARGO. In 2020, they founded and became Chair of Gabriel Precision Oncology. In 2018, they were appointed Research Collaborator at Mayo Clinic. In 2014, they were appointed Visiting Scientist at Wellcome Sanger Institute. In 2016, they were appointed Therapeutic Board Member at Precision-Panc. In 2017, they were appointed Head of Research and Translational Medicine and Head of Translational Medicine at Karus Therapeutics Limited.

Philip Beer's education history includes completing a PhD at the University of Cambridge from 2005 to 2008. From 1991 to 1996, they obtained a BMedSci; BM, BS from the University of Nottingham. Philip also holds a FRCPath from the Royal College of Pathologists since 2004 and a MRCP from the Royal College of Physicians since 1999.